Rituxan®

BIOLOGICAL2 trials

Sponsors

Boehringer Ingelheim, Mabion SA

Conditions

Arthritis, RheumatoidRheumatoid Arthritis

Phase 3

Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis

TerminatedNCT01682512

Boehringer IngelheimArthritis, Rheumatoid

Start: 2012-09-05End: 2016-10-12Updated: 2018-01-30

MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis

WithdrawnNCT04680962

Mabion SARheumatoid Arthritis

Start: 2023-08-03End: 2023-08-03Updated: 2023-08-07